Published 2 years ago • loading... • Updated 2 years ago

Bristol Myers to buy cancer therapy company in $4.1 billion deal

Bristol Myers Squibb will acquire cancer drug developer RayzeBio for $4.1 billion, allowing Bristol Myers to enter the radiopharmaceutical therapeutics field.
The acquisition includes RayzeBio's new manufacturing facility in Indianapolis, expected to begin production in the first half of 2024.
RayzeBio's CEO praised Bristol Myers as the ideal partner, noting their expertise in developing and commercializing treatments on a global scale.

Insights by Ground AI

14 Articles

Bristol Myers to buy cancer therapy company in $4.1 billion deal

Bristol Myers Squibb on Tuesday announced a deal to acquire RayzeBio in an effort to expand the drugmaker’s cancer treatment offerings. The acquisition was for a total equity value of about $4.1 billion, at $62.50 per share. RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company, has several cancer treatments under development, specifically ones targeting the treatment…

2 years ago·Washington, United States

Read Full Article

Investor's Business Daily

Lean Right

BMY Stock: Bristol Myers Buying RayzeBio For $4.1 Billion; RYZB Soars

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

2 years ago

Read Full Article

Benzinga

Center

Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio - RayzeBio (NASDAQ:RYZB), Bristol-Myers Squibb (NYSE:BMY)

2 years ago·New York, United States

Read Full Article

Axios

Lean Left

Bristol Myers to buy RayzeBio for $4.1B

2 years ago·Washington, United States

Read Full Article

Bloomberg

Lean Left

Bristol Adds to Buying Spree With $4.1 Billion Drugmaker Deal

Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline.

2 years ago·United States

Read Full Article